Lei Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lei Yin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ai-Jun Li
Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, 225 Changhai Road, Shanghai, China
4 shared publications - Meng-Chao Wu
Department of Second Special Treatment, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai, China
2 shared publications Si-Yuan Fu
2 shared publications- Wei-Ping Zhou
The 3rd Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China
2 shared publications - Wei-Ping Zhou
The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
2 shared publications - Ze-Ya Pan
The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 200438, Shanghai, China.
2 shared publications
Latest Publications
- Open Access
- 1 July 2020
- Published by Springer Nature in Cell & Bioscience
- Vol. 10 (1) , 1-12
MicroRNA let-7b inhibits cell proliferation via upregulation of p21 in hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the most malignant tumor types and has a high incidence and mortality. Many miRNAs play important roles in the development of HCC. Identification of these miRNAs and their targets is increasingly urgent for a better understandingof miRNA function in both physiological and pathological contexts. Many studies have shown that the expression of let-7 is often downregulated in the process of tumorigenesis, suggesting that let-7 may participate in this process as an oncogene. Methods: Immunochemistry staining was used to observe the expression of let-7b in HCC tissues. A CCK-8 assay was employed to detect the role of let-7b in the proliferation of HCC cells. The cell cycle of HCC cells was examined by flow cytometry. BALB/c nu/nu mice were used to detect the tumorigenesis potential of HCC cells; western blot and real-time PCR were employed to observe the expression of p21 in HCC cells. Results: In our previous studies investigating HCC tissue samples obtained from the national tissue samples bank of liver cancer in Eastern Hepatobiliary Surgery Hospital, we found one abnormal expression of miRNA (let-7b), which was significantly downregulated in HCC tissue. In the current work, we studied the relationship between let-7b and HCC to potentially provide invaluable information for developing novel therapeutic strategies for treating HCC. Based on our findings, let-7b expression was absent in HCC tumors, and its lower expression was associated with poor prognosis of HCC. In further experiments, we found that let-7b inhibited HCC cell proliferation through upregulation of p21. Conclusion: The results of our study suggested that let-7b might inhibit the proliferation of HCC cells by upregulating p21.
- 1 July 2020
- Published by Springer Nature in Cell & Bioscience
- Vol. 10 (1) , 1-12
Open AccessMicroRNA let-7b inhibits cell proliferation via upregulation of p21 in hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the most malignant tumor types and has a high incidence and mortality. Many miRNAs play important roles in the development of HCC. Identification of these miRNAs and their targets is increasingly urgent for a better understandingof miRNA function in both physiological and pathological contexts. Many studies have shown that the expression of let-7 is often downregulated in the process of tumorigenesis, suggesting that let-7 may participate in this process as an oncogene. Methods: Immunochemistry staining was used to observe the expression of let-7b in HCC tissues. A CCK-8 assay was employed to detect the role of let-7b in the proliferation of HCC cells. The cell cycle of HCC cells was examined by flow cytometry. BALB/c nu/nu mice were used to detect the tumorigenesis potential of HCC cells; western blot and real-time PCR were employed to observe the expression of p21 in HCC cells. Results: In our previous studies investigating HCC tissue samples obtained from the national tissue samples bank of liver cancer in Eastern Hepatobiliary Surgery Hospital, we found one abnormal expression of miRNA (let-7b), which was significantly downregulated in HCC tissue. In the current work, we studied the relationship between let-7b and HCC to potentially provide invaluable information for developing novel therapeutic strategies for treating HCC. Based on our findings, let-7b expression was absent in HCC tumors, and its lower expression was associated with poor prognosis of HCC. In further experiments, we found that let-7b inhibited HCC cell proliferation through upregulation of p21. Conclusion: The results of our study suggested that let-7b might inhibit the proliferation of HCC cells by upregulating p21.
- 1 August 2014
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 28 (6) , 1565.e5-1565.e8
Cavoatrial Thrombectomy in Hepatocellular Carcinoma with Tumor Thrombus in the Vena Cava and Atrium Without the Use of Cardiopulmonary Bypass
- 1 August 2014
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 28 (6) , 1565.e5-1565.e8
Cavoatrial Thrombectomy in Hepatocellular Carcinoma with Tumor Thrombus in the Vena Cava and Atrium Without the Use of Cardiopulmonary Bypass
- Open Access
- 1 January 2014
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 5 (11) , 882-885
Surgery for pregnancy-associated primary hepatocellular carcinoma
INTRODUCTION: Hepatocellular carcinoma (HCC) occurring in pregnancy is quite rare. The prognosis is usually poor because of a delay in diagnosis. Reported cases of HCC in pregnancy are largely isolated with no large experience. Thus the effect of pregnancy on the prognosis of patients with HCC and the risk factors of developing HCC in pregnancy are not well documented. Our aim was to review our experience with management of four young pregnant women with HCC. PRESENTATION OF CASE: Laboratory tests were performed before surgery. We analyzed the effects of age, hepatitis B surface antigens status, cirrhosis at presentation, gestational age of fetus, and maternal outcome. DISCUSSION: Increase in alpha-fetoprotein (AFP) level was somewhat useful for diagnosis. Three patients died in 5 months, 6 months, and 24 months from HCC recurrence, and another patient is alive without disease 12 months postoperatively. CONCLUSION: Surgery for HCC during pregnancy should be similar to that for non-pregnant women. Complete excision of tumor without termination of pregnancy provides the greatest chance of survival for women with HCC during pregnancy but depends on gestational age of the fetus. Adjuvant treatments are required to improve the long-term results of this type of surgery. The 28-week gestational week is a critical point of fetal maturation which is very important in deciding whether pregnancy should be terminated or not. The pregnancy was terminated in two of our patients when spontaneous rupture of HCC was diagnosed to save the mother's life.
- 1 January 2014
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 5 (11) , 882-885
Open AccessSurgery for pregnancy-associated primary hepatocellular carcinoma
INTRODUCTION: Hepatocellular carcinoma (HCC) occurring in pregnancy is quite rare. The prognosis is usually poor because of a delay in diagnosis. Reported cases of HCC in pregnancy are largely isolated with no large experience. Thus the effect of pregnancy on the prognosis of patients with HCC and the risk factors of developing HCC in pregnancy are not well documented. Our aim was to review our experience with management of four young pregnant women with HCC. PRESENTATION OF CASE: Laboratory tests were performed before surgery. We analyzed the effects of age, hepatitis B surface antigens status, cirrhosis at presentation, gestational age of fetus, and maternal outcome. DISCUSSION: Increase in alpha-fetoprotein (AFP) level was somewhat useful for diagnosis. Three patients died in 5 months, 6 months, and 24 months from HCC recurrence, and another patient is alive without disease 12 months postoperatively. CONCLUSION: Surgery for HCC during pregnancy should be similar to that for non-pregnant women. Complete excision of tumor without termination of pregnancy provides the greatest chance of survival for women with HCC during pregnancy but depends on gestational age of the fetus. Adjuvant treatments are required to improve the long-term results of this type of surgery. The 28-week gestational week is a critical point of fetal maturation which is very important in deciding whether pregnancy should be terminated or not. The pregnancy was terminated in two of our patients when spontaneous rupture of HCC was diagnosed to save the mother's life.
- 1 September 2011
- Vol. 13 (9) , 755-6
[Etiology of childhood erythema nodosum in 23 cases].
- 13 August 2011
- Vol. 58, 887-91
Primary hepatic malignant fibrous histiocytoma: diagnostic pitfalls and therapeutic challenge.
Due to the rarity of primary hepatic malignant fibrous histiocytoma (MFH), the natural history, optimal management and prognosis are poorly characterized. Between January 2003 and December 2008, we treated 12 consecutive patients with primary hepatic MFH. The patient demographics, tumor characteristics, type of treatment and actuarial survival were analyzed. The mean +/- SD tumor size was 8.4 +/- 3.2cm. Four patients had satellite lesions. R0, R1 and R2 resection of the liver tumor were achieved in 5, 2 and 5 patients, respectively. There was no hospital mortality and the complication rate was 8.3%. At a median follow-up of 11.3 months, local recurrence had occurred in 6 patients and local recurrence + distant metastases in 3 patients. Most patients (8/12) died of the tumor within a year after surgery, with a median survival of 6.1 months. For the remaining 4 patients, 2 patients had undergone surgery for less than 1 year previously, one patient who had a R0 liver resection with extrahepatic metastasis survived for 14 months with multiple metastases, and another patient who had a R0 liver resection but without extrahepatic metastasis survived for 60 months and was disease free. The median survival for the R0 liver resection group carried out in patients without extrahepatic metastases was 8.5 months, while the median survival of the debulking group (R0 liver resection with extrahepatic metastasis/ R1 or R2 liver resection) was 7 months. There was no significant difference in survival between the two groups. Hepatic resection was safe for patients with primary MFH with a poor prognosis. Complete resection offers the only hope of long-term disease free survival.
- 13 August 2011
- Vol. 58, 887-91
Primary hepatic malignant fibrous histiocytoma: diagnostic pitfalls and therapeutic challenge.
Due to the rarity of primary hepatic malignant fibrous histiocytoma (MFH), the natural history, optimal management and prognosis are poorly characterized. Between January 2003 and December 2008, we treated 12 consecutive patients with primary hepatic MFH. The patient demographics, tumor characteristics, type of treatment and actuarial survival were analyzed. The mean +/- SD tumor size was 8.4 +/- 3.2cm. Four patients had satellite lesions. R0, R1 and R2 resection of the liver tumor were achieved in 5, 2 and 5 patients, respectively. There was no hospital mortality and the complication rate was 8.3%. At a median follow-up of 11.3 months, local recurrence had occurred in 6 patients and local recurrence + distant metastases in 3 patients. Most patients (8/12) died of the tumor within a year after surgery, with a median survival of 6.1 months. For the remaining 4 patients, 2 patients had undergone surgery for less than 1 year previously, one patient who had a R0 liver resection with extrahepatic metastasis survived for 14 months with multiple metastases, and another patient who had a R0 liver resection but without extrahepatic metastasis survived for 60 months and was disease free. The median survival for the R0 liver resection group carried out in patients without extrahepatic metastases was 8.5 months, while the median survival of the debulking group (R0 liver resection with extrahepatic metastasis/ R1 or R2 liver resection) was 7 months. There was no significant difference in survival between the two groups. Hepatic resection was safe for patients with primary MFH with a poor prognosis. Complete resection offers the only hope of long-term disease free survival.
- 20 September 2010
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 30 (9) , 1006-1009
Diagnosis and treatment of pulmonary embolism secondary to hepatectomy in patients with hepatic tumors
- 20 September 2010
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 30 (9) , 1006-1009
Diagnosis and treatment of pulmonary embolism secondary to hepatectomy in patients with hepatic tumors
- 1 February 2007
- Vol. 9 (1) , 77-8
[Clinical analysis of 25 cases of enthesitis related juvenile idiopathic arthritis].
- 1 February 2007
- Vol. 9 (1) , 77-8
[Clinical analysis of 25 cases of enthesitis related juvenile idiopathic arthritis].